Literature DB >> 25604491

α-Thalassaemia trait is associated with antibody prevalence against malaria antigens AMA-1 and MSP-1.

Modibo Daou1, Elimsaada Kituma2, Reginald Kavishe2, Jaffu Chilongola2, Frank Mosha2, André van der Ven3, Bourema Kouriba4, Teun Bousema5, Robert Sauerwein6, Ogobaro Doumbo4.   

Abstract

A longitudinal study was conducted in a low endemic area in northern Tanzania to examine the influence of the α-thalassaemia trait on malaria incidence and antibody responses to malaria apical membrane antigen-1 (AMA-1) and merozoite surface protein1-19 (MSP-119). Out of 394 children genotyped for α-thalassaemia trait, 4.1% (16 of 394) and 30.7% (121 of 394) were homozygous and heterozygous, respectively. During the 1 year follow-up, four incidents of malaria cases were detected without an evident association with α-thalassaemia. Being heterozygous or homozygous for α-thalassaemia was associated with an increased prevalence of antibodies to AMA-1 [odds ratio (OR): 1.83, 95% confidence interval (CI): 1.07-3.12, p = 0.027] and MSP-1 (OR: 2.04, 95% CI: 1.16-3.60, p = 0.013) after adjustment for age and reported bednet use. The observed association between α-thalassaemia and malaria antibody responses may reflect longer-term differences in antigen exposure or differences in antibody acquisition upon exposure in this low endemic setting.
© The Author [2015]. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  immunity; malaria; thalassaemia

Mesh:

Substances:

Year:  2015        PMID: 25604491     DOI: 10.1093/tropej/fmu077

Source DB:  PubMed          Journal:  J Trop Pediatr        ISSN: 0142-6338            Impact factor:   1.165


  1 in total

1.  Prevalence of Plasmodium falciparum and Salmonella typhi Infection and Coinfection and Their Association With Fever in Northern Tanzania.

Authors:  Jaffu Chilongola; Sophia Kombe; Pius Horumpende; Rebeka Nazareth; Elias Sabuni; Arnold Ndaro; Eliakimu Paul
Journal:  East Afr Health Res J       Date:  2018-11-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.